Post

We've got some very exciting news to share! businesswire.com/news/home/20... and here's a 🧵 about the journey from academia to @aiproteins.bsky.social

businesswire.comAI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400MAI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, today announced that

3/12/24, 2:49 pm1 repost9 likes

Chris Bahl

@cdbahl.com

3 Dec 2024

I started working on designing #miniproteins de novo in 2012 when I joined David Baker's lab for my postdoc at the newly formed @uwproteindesign.bsky.social. Back then, it had never been done before.

Chris Bahl

@cdbahl.com

3 Dec 2024

I still remember the excitement when I got it to work for the first time ever, which was followed closely by a realization of what these molecules could do to benefit humanity.

Chris Bahl

@cdbahl.com

3 Dec 2024

In 2021, I quit my faculty job at @ipiproteins.bsky.social, @bostonchildrens.bsky.social and @harvardmed.bsky.social and cancelled all my grants and sponsored research.

Chris Bahl

@cdbahl.com

3 Dec 2024

In my academic lab, my research group and I had established the first version of a high-throughput #miniprotein design and engineering platform that united artificial intelligence, synthetic biology, and robotics.